Handelen Amgen - AMGN CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 1.00 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.030779% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | -0.013666% | ||||||||
Tijd van overnight-tarief | 22:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Amgen Inc ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Prev. Close* | 245.61 |
Open* | 247.59 |
1-Jaarlijkse Verandering* | 8.35% |
Dagelijks bereik* | 242.22 - 247.59 |
52 wekelijks bereik | 214.39-296.67 |
Weekgemiddelde volume (10 dagen) | 2.95M |
Gemiddeld volume (3 maanden) | 55.89M |
Marktkapitalisatie | 130.92B |
P/E Ratio | 20.24 |
Uitstaande Aandelen | 534.00M |
Omzet | 26.32B |
EPS | 12.11 |
Dividend (opbrengst %) | 3.47514 |
Beta | 0.63 |
Volgende inkomsten datum | Feb 6, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 244.57 | -3.44 | -1.39% | 248.01 | 249.24 | 241.75 |
Feb 2, 2023 | 245.61 | 2.54 | 1.04% | 243.07 | 246.19 | 235.61 |
Feb 1, 2023 | 245.85 | -2.80 | -1.13% | 248.65 | 248.87 | 239.66 |
Jan 31, 2023 | 251.50 | 0.06 | 0.02% | 251.44 | 252.27 | 249.46 |
Jan 30, 2023 | 251.22 | -0.27 | -0.11% | 251.49 | 253.64 | 250.16 |
Jan 27, 2023 | 253.18 | -1.00 | -0.39% | 254.18 | 254.78 | 252.16 |
Jan 26, 2023 | 254.36 | -0.58 | -0.23% | 254.94 | 256.12 | 252.57 |
Jan 25, 2023 | 256.02 | -3.70 | -1.42% | 259.72 | 261.13 | 255.52 |
Jan 24, 2023 | 259.11 | -0.41 | -0.16% | 259.52 | 261.45 | 256.93 |
Jan 23, 2023 | 260.45 | -2.68 | -1.02% | 263.13 | 264.27 | 259.31 |
Jan 20, 2023 | 262.82 | 3.73 | 1.44% | 259.09 | 263.44 | 258.02 |
Jan 19, 2023 | 261.49 | 0.26 | 0.10% | 261.23 | 263.11 | 260.31 |
Jan 18, 2023 | 263.82 | -5.06 | -1.88% | 268.88 | 269.60 | 262.76 |
Jan 17, 2023 | 268.83 | -1.89 | -0.70% | 270.72 | 273.40 | 268.32 |
Jan 13, 2023 | 271.36 | 2.20 | 0.82% | 269.16 | 271.74 | 269.16 |
Jan 12, 2023 | 270.44 | 0.00 | 0.00% | 270.44 | 271.57 | 268.00 |
Jan 11, 2023 | 272.26 | -2.85 | -1.04% | 275.11 | 275.97 | 269.55 |
Jan 10, 2023 | 273.41 | 4.07 | 1.51% | 269.34 | 274.15 | 268.61 |
Jan 9, 2023 | 269.67 | -3.70 | -1.35% | 273.37 | 274.39 | 268.16 |
Jan 6, 2023 | 274.64 | 7.41 | 2.77% | 267.23 | 276.36 | 267.23 |
Amgen Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Jaarlijks
- Per kwartaal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Totale inkomsten | 22991 | 22849 | 23747 | 23362 | 25424 | 25979 |
Inkomsten | 22991 | 22849 | 23747 | 23362 | 25424 | 25979 |
Kosten van opbrengsten, totaal | 4162 | 4069 | 4101 | 4356 | 6159 | 6454 |
Brutowinst | 18829 | 18780 | 19646 | 19006 | 19265 | 19525 |
Totale bedrijfskosten | 13197 | 12876 | 13404 | 13688 | 16285 | 18340 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 5062 | 4870 | 5332 | 5150 | 5730 | 6873 |
Onderzoek & Ontwikkeling | 3840 | 3562 | 3737 | 4116 | 4207 | 4819 |
Ongebruikelijke uitgaven (inkomsten) | -6 | 367 | 292 | 47 | ||
Other Operating Expenses, Total | 139 | 8 | -58 | 19 | 189 | 194 |
Bedrijfsresultaat | 9794 | 9973 | 10343 | 9674 | 9139 | 7639 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -631 | -376 | -798 | -536 | -1006 | -1197 |
Netto inkomen voor belastingen | 9163 | 9597 | 9545 | 9138 | 8133 | 6701 |
Netto inkomen na belastingen | 7722 | 8079 | 8394 | 7842 | 7264 | 5893 |
Netto inkomen voor extra. Posten | 7722 | 8079 | 8394 | 7842 | 7264 | 5893 |
Netto inkomen | 7722 | 1979 | 8394 | 7842 | 7264 | 5893 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 7722 | 8079 | 8394 | 7842 | 7264 | 5893 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 7722 | 1979 | 8394 | 7842 | 7264 | 5893 |
Verwaterd Netto Inkomen | 7722 | 1979 | 8394 | 7842 | 7264 | 5893 |
Verwaterd Gewogen Gemiddelde Aandelen | 754 | 735 | 665 | 609 | 590 | 573 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 10.2414 | 10.9918 | 12.6226 | 12.8769 | 12.3119 | 10.2845 |
Dividends per Share - Common Stock Primary Issue | 4 | 4.6 | 5.28 | 5.8 | 6.4 | 7.04 |
Verwaterde Genormaliseerde Winst per Aandeel | 10.2347 | 11.4122 | 13.0087 | 12.9431 | 12.3119 | 10.2845 |
Totale buitengewone posten | -6100 | |||||
Overige, Netto | 259 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Totale inkomsten | 5901 | 6526 | 6706 | 6846 | 6238 |
Inkomsten | 5901 | 6526 | 6706 | 6846 | 6238 |
Kosten van opbrengsten, totaal | 1490 | 1637 | 1609 | 1718 | 1561 |
Brutowinst | 4411 | 4889 | 5097 | 5128 | 4677 |
Totale bedrijfskosten | 3772 | 5698 | 4328 | 4542 | 3738 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 1254 | 2889 | 1305 | 1425 | 1228 |
Onderzoek & Ontwikkeling | 967 | 1082 | 1422 | 1348 | 959 |
Other Operating Expenses, Total | 61 | 90 | -8 | 51 | -10 |
Bedrijfsresultaat | 2129 | 828 | 2378 | 2304 | 2500 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -285 | -281 | -296 | -335 | -295 |
Overige, Netto | 13 | 11 | 73 | 162 | -530 |
Netto inkomen voor belastingen | 1857 | 558 | 2155 | 2131 | 1675 |
Netto inkomen na belastingen | 1646 | 464 | 1884 | 1899 | 1476 |
Netto inkomen voor extra. Posten | 1646 | 464 | 1884 | 1899 | 1476 |
Netto inkomen | 1646 | 464 | 1884 | 1899 | 1476 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 1646 | 464 | 1884 | 1899 | 1476 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 1646 | 464 | 1884 | 1899 | 1476 |
Verwaterd Netto Inkomen | 1646 | 464 | 1884 | 1899 | 1476 |
Verwaterd Gewogen Gemiddelde Aandelen | 581 | 576 | 570 | 564 | 551 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 2.83305 | 0.80556 | 3.30526 | 3.36702 | 2.67877 |
Dividends per Share - Common Stock Primary Issue | 1.76 | 1.76 | 1.76 | 1.76 | 1.94 |
Verwaterde Genormaliseerde Winst per Aandeel | 2.83305 | 0.80556 | 3.30526 | 3.36702 | 2.67877 |
- Jaarlijks
- Per kwartaal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Totaal vlottende activa | 46010 | 49476 | 37618 | 18440 | 21144 | 19385 |
Geldmiddelen en kortetermijnbeleggingen | 38085 | 41678 | 29304 | 8911 | 10647 | 8037 |
Geldmiddelen & Equivalenten | 3241 | 3800 | 6945 | 6037 | 6266 | 7989 |
Korte Termijn Investeringen | 34844 | 37878 | 22359 | 2874 | 4381 | 48 |
Totale Vorderingen, Netto | 3165 | 3237 | 3580 | 4057 | 5324 | 5839 |
Accounts Receivable - Trade, Net | 3165 | 3237 | 3580 | 4057 | 4525 | 4895 |
Total Inventory | 2745 | 2834 | 2940 | 3584 | 3893 | 4086 |
Other Current Assets, Total | 2015 | 1727 | 1794 | 1888 | 124 | 200 |
Total Assets | 77626 | 79954 | 66416 | 59707 | 62948 | 61165 |
Property/Plant/Equipment, Total - Net | 4961 | 4989 | 4958 | 5397 | 5297 | 5750 |
Property/Plant/Equipment, Total - Gross | 12427 | 12579 | 12754 | 13754 | 14274 | 14548 |
Accumulated Depreciation, Total | -7466 | -7590 | -7796 | -8357 | -8977 | -8798 |
Goodwill, Net | 14751 | 14761 | 14699 | 14703 | 14689 | 14890 |
Intangibles, Net | 10279 | 8609 | 7443 | 19413 | 16587 | 15182 |
Long Term Investments | 501 | 570 | 1176 | 573 | ||
Other Long Term Assets, Total | 1124 | 1549 | 1698 | 1754 | 4055 | 5385 |
Total Current Liabilities | 11204 | 9020 | 13488 | 12835 | 11653 | 12184 |
Accounts Payable | 917 | 1352 | 1207 | 1371 | 1421 | 1366 |
Accrued Expenses | 4964 | 5563 | 6948 | 7565 | 8295 | 8947 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4403 | 1152 | 4419 | 2953 | 91 | 87 |
Other Current Liabilities, Total | 920 | 953 | 914 | 946 | 1846 | 1784 |
Total Liabilities | 47751 | 54713 | 53916 | 50034 | 53539 | 54465 |
Total Long Term Debt | 30193 | 34190 | 29510 | 26950 | 32895 | 33222 |
Long Term Debt | 30193 | 34190 | 29510 | 26950 | 32895 | 33222 |
Deferred Income Tax | 2436 | 1166 | 864 | 606 | ||
Other Liabilities, Total | 3918 | 10337 | 10054 | 9643 | 8991 | 9059 |
Total Equity | 29875 | 25241 | 12500 | 9673 | 9409 | 6700 |
Common Stock | 30784 | 30992 | 31246 | 31531 | 31802 | 32096 |
Retained Earnings (Accumulated Deficit) | -438 | -5072 | -17977 | -21330 | -21408 | -24600 |
Unrealized Gain (Loss) | -138 | -144 | -338 | 22 | 1 | |
Other Equity, Total | -333 | -535 | -431 | -550 | -986 | -796 |
Total Liabilities & Shareholders’ Equity | 77626 | 79954 | 66416 | 59707 | 62948 | 61165 |
Total Common Shares Outstanding | 738.2 | 722.2 | 629.6 | 591.4 | 578.3 | 558.3 |
Prepaid Expenses | 1156 | 1223 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Totaal vlottende activa | 21299 | 19099 | 24380 | 19385 | 18520 |
Geldmiddelen en kortetermijnbeleggingen | 10566 | 8082 | 12921 | 8037 | 6544 |
Geldmiddelen & Equivalenten | 6112 | 6630 | 11969 | 7989 | 6528 |
Korte Termijn Investeringen | 4454 | 1452 | 952 | 48 | 16 |
Totale Vorderingen, Netto | 4423 | 4479 | 4765 | 4895 | 5077 |
Accounts Receivable - Trade, Net | 4423 | 4479 | 4765 | 4895 | 5077 |
Total Inventory | 4017 | 4115 | 4152 | 4086 | 4411 |
Other Current Assets, Total | 2293 | 2423 | 2542 | 2367 | 2488 |
Total Assets | 62539 | 59773 | 64993 | 61165 | 59196 |
Property/Plant/Equipment, Total - Net | 4855 | 4906 | 4982 | 5184 | 5142 |
Goodwill, Net | 14673 | 14676 | 14665 | 14890 | 14897 |
Intangibles, Net | 15947 | 15308 | 14659 | 15182 | 14567 |
Other Long Term Assets, Total | 5765 | 5784 | 6307 | 6524 | 6070 |
Total Current Liabilities | 12869 | 14585 | 14842 | 12184 | 12886 |
Accounts Payable | 1396 | 1277 | 1171 | 1366 | 1403 |
Accrued Expenses | 9917 | 8984 | 9383 | 10731 | 10639 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1556 | 4324 | 4288 | 87 | 844 |
Total Liabilities | 53205 | 51526 | 56776 | 54465 | 58280 |
Total Long Term Debt | 31129 | 28458 | 33291 | 33222 | 36010 |
Long Term Debt | 31129 | 28458 | 33291 | 33222 | 36010 |
Other Liabilities, Total | 9207 | 8483 | 8643 | 9059 | 9384 |
Total Equity | 9334 | 8247 | 8217 | 6700 | 916 |
Common Stock | 31806 | 31877 | 31989 | 32096 | 31247 |
Retained Earnings (Accumulated Deficit) | -21639 | -22762 | -22964 | -24600 | -29568 |
Unrealized Gain (Loss) | 1 | 1 | 0 | 0 | |
Other Equity, Total | -834 | -869 | -808 | -796 | -763 |
Total Liabilities & Shareholders’ Equity | 62539 | 59773 | 64993 | 61165 | 59196 |
Total Common Shares Outstanding | 575.3 | 569.6 | 565 | 558.3 | 534.2 |
- Jaarlijks
- Per kwartaal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | 7722 | 1979 | 8394 | 7842 | 7264 | 5893 |
Geldmiddelen uit Operationele Activiteiten | 10354 | 11177 | 11296 | 9150 | 10497 | 9261 |
Geldmiddelen uit Operationele Activiteiten | 2105 | 1955 | 1946 | 2206 | 3601 | 3398 |
Deferred Taxes | 183 | -1330 | -363 | -289 | -287 | -453 |
Niet-Geldelijke Posten | 343 | 663 | 697 | 122 | 135 | 1617 |
Cash Taxes Paid | 1100 | 1500 | 1900 | 1900 | 1400 | 1900 |
Contant Betaalde Rente | 1300 | 1300 | 1500 | 1300 | 1200 | 1200 |
Veranderingen in het Operationeel Kapitaal | 1 | 7910 | 622 | -731 | -216 | -1194 |
Geldmiddelen uit Investeringsactiviteiten | -8658 | -4024 | 14339 | 5709 | -5401 | 733 |
Kapitaaluitgaven | -837 | -664 | -738 | -618 | -608 | -880 |
Overige Cash Flow investeringsposten, Totaal | -7821 | -3360 | 15077 | 6327 | -4793 | 1613 |
Geldmiddelen uit Financieringsactiviteiten | -2599 | -6594 | -22490 | -15767 | -4867 | -8271 |
Financiering van Cash Flow Posten | -284 | -140 | -68 | -42 | -90 | -78 |
Total Cash Dividends Paid | -2998 | -3365 | -3507 | -3509 | -3755 | -4013 |
Uitgifte (Aflossing) van aandelen, netto | -2910 | -3160 | -17794 | -7702 | -3486 | -4975 |
Uitgifte (Aflossing) van Schulden, Netto | 3593 | 71 | -1121 | -4514 | 2464 | 795 |
Nettowijziging in Geldmiddelen | -903 | 559 | 3145 | -908 | 229 | 1723 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1646 | 2110 | 3994 | 5893 | 1476 |
Cash From Operating Activities | 2104 | 4035 | 6453 | 9261 | 2164 |
Cash From Operating Activities | 841 | 1696 | 2546 | 3398 | 841 |
Deferred Taxes | -91 | -137 | -264 | -453 | -251 |
Non-Cash Items | 79 | 1675 | 1692 | 1617 | 545 |
Changes in Working Capital | -371 | -1309 | -1515 | -1194 | -447 |
Cash From Investing Activities | -319 | 890 | 963 | 733 | -111 |
Capital Expenditures | -166 | -351 | -593 | -880 | -190 |
Other Investing Cash Flow Items, Total | -153 | 1241 | 1556 | 1613 | 79 |
Cash From Financing Activities | -1939 | -4561 | -1713 | -8271 | -3514 |
Financing Cash Flow Items | -52 | -85 | -104 | -78 | -26 |
Total Cash Dividends Paid | -1016 | -2024 | -3023 | -4013 | -1080 |
Issuance (Retirement) of Stock, Net | -871 | -2452 | -3532 | -4975 | -6360 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 4946 | 795 | 3952 |
Net Change in Cash | -154 | 364 | 5703 | 1723 | -1461 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.842 | 47216165 | 1317764 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.459 | 29151093 | 277320 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.4444 | 29073061 | -207866 | 2022-09-30 | LOW |
PRIMECAP Management Company | Investment Advisor | 2.9148 | 15564870 | -73750 | 2022-09-30 | LOW |
Capital Research Global Investors | Investment Advisor | 2.3605 | 12605265 | -1490071 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.0975 | 11200793 | 502787 | 2022-09-30 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 1.7297 | 9236530 | 287899 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.5254 | 8145601 | -212030 | 2022-09-30 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 1.5243 | 8139945 | -45470 | 2022-09-30 | LOW |
Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.333 | 7118039 | -705787 | 2022-12-31 | LOW |
Wells Fargo Advisors | Research Firm | 1.324 | 7070379 | 59546 | 2022-09-30 | LOW |
Goldman Sachs & Company, Inc. | Research Firm | 1.2358 | 6599371 | 1971000 | 2022-09-30 | MED |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.9481 | 5062588 | -492241 | 2021-12-31 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.9186 | 4905395 | 163471 | 2022-09-30 | LOW |
Aristotle Capital Management, LLC | Investment Advisor | 0.9158 | 4890166 | -72128 | 2022-09-30 | LOW |
BofA Global Research (US) | Research Firm | 0.8955 | 4781857 | -445255 | 2022-09-30 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.8086 | 4317814 | -103045 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7969 | 4255525 | -170586 | 2022-09-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7683 | 4102655 | -193979 | 2022-09-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 0.7668 | 4094846 | 20049 | 2022-09-30 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com GroupHandelaren
Actieve klanten per maand
Maandelijks beleggingsvolume
Opgenomen per maand
Handelscalculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Amgen Company profile
Over Amgen
Amgen Inc. is een biotechnologiebedrijf. Het bedrijf ontdekt, ontwikkelt, produceert en levert verschillende menselijke therapeutica. Het is actief in het segment menselijke therapeutica. Zijn portefeuille van op de markt gebrachte producten omvat Neulasta (pegfilgrastim); erytropoëse-stimulerende middelen (ESA's), zoals Aranesp (darbepoetine alfa) en EPOGEN (epoëtine alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), en andere op de markt gebrachte producten, zoals KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) en Corlanor (ivabradine). Het concentreert zich op menselijke therapeutica voor de behandeling van ernstige ziekten in de domeinen oncologie/hematologie, cardiovasculaire aandoeningen en neurowetenschappen. Zijn productkandidaten in Fase III omvatten Erenumab voor episodische migraine, Aranesp voor myelodysplastische syndromen, BLINCYTO voor acute lymfoblastische leukemie en IMLYGIC voor metastatisch melanoom.
Industry: | Pharmaceuticals (NEC) |
One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 485.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen